Blocking a key enzyme in Alzheimer's patients' immune cells shifted them from inflammatory to protective
Inhibiting FAAH in monocytes from Alzheimer's patients reduced pro-inflammatory cytokines and shifted macrophages toward an anti-inflammatory, neuroprotective state.
Quick Facts
What This Study Found
AD patients had lower CB1 and CB2 expression on B-lymphocytes and monocytes, with higher FAAH levels in monocytes. Blocking FAAH in these cells reduced TNF-alpha, IL-6, and IL-12 while increasing anti-inflammatory IL-10, and shifted macrophages toward a more protective phenotype. Monocytic CB2 and FAAH levels correlated with clinical scores.
Key Numbers
CB1 and CB2 lower in AD B-lymphocytes; CB2 lower and FAAH higher in AD monocytes; FAAH blockade reduced TNF-alpha, IL-6, IL-12 and increased IL-10; T-lymphocytes and NK cells showed no changes
How They Did This
Comparison of endocannabinoid system markers on immune cells from AD patients versus healthy controls, followed by in vitro pharmacological FAAH inhibition experiments on patient-derived monocytes and macrophages.
Why This Research Matters
If peripheral immune cells contribute to Alzheimer's progression, and their inflammatory behavior can be modulated through the endocannabinoid system, this opens a novel therapeutic approach targeting immune cells rather than brain cells directly.
The Bigger Picture
This supports a growing understanding that Alzheimer's involves peripheral immune dysregulation, and that the endocannabinoid system could be leveraged to shift immune cells from harmful to protective roles.
What This Study Doesn't Tell Us
In vitro manipulation may not translate to in vivo effects. Cross-sectional design cannot establish causation. Small sample size typical of such studies. Effects on disease progression were not measured.
Questions This Raises
- ?Would systemic FAAH inhibition reduce neuroinflammation in AD patients?
- ?Could peripheral immune markers be used to monitor AD progression?
- ?Are there FAAH inhibitors suitable for clinical trials in AD?
Trust & Context
- Key Stat:
- FAAH inhibition reduced pro-inflammatory and increased anti-inflammatory cytokines in AD monocytes
- Evidence Grade:
- In vitro study using cells from AD patients, providing mechanistic insight but not clinical evidence
- Study Age:
- Published in 2021. FAAH inhibitors for neurodegenerative diseases remain in early research stages.
- Original Title:
- Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.
- Published In:
- Biomolecules, 11(4) (2021)
- Authors:
- Chiurchiù, Valerio(3), Scipioni, Lucia(3), Arosio, Beatrice(2), Mari, Daniela, Oddi, Sergio, Maccarrone, Mauro
- Database ID:
- RTHC-03059
Evidence Hierarchy
A snapshot of a population at one point in time.
What do these levels mean? →Frequently Asked Questions
Could targeting the endocannabinoid system help with Alzheimer's?
This study found that blocking FAAH in immune cells from AD patients reduced inflammation and shifted them toward a protective state. This suggests a potential therapeutic approach, though clinical testing is needed.
What is FAAH and why does it matter?
FAAH is an enzyme that breaks down endocannabinoids. It was found at higher levels in AD patients' monocytes. Blocking it enhanced anti-inflammatory endocannabinoid signaling, which could help create a more neuroprotective environment.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03059APA
Chiurchiù, Valerio; Scipioni, Lucia; Arosio, Beatrice; Mari, Daniela; Oddi, Sergio; Maccarrone, Mauro. (2021). Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.. Biomolecules, 11(4). https://doi.org/10.3390/biom11040502
MLA
Chiurchiù, Valerio, et al. "Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhibition in Monocytes/Macrophages from Alzheimer's Disease Patients.." Biomolecules, 2021. https://doi.org/10.3390/biom11040502
RethinkTHC
RethinkTHC Research Database. "Anti-Inflammatory Effects of Fatty Acid Amide Hydrolase Inhi..." RTHC-03059. Retrieved from https://rethinkthc.com/research/chiurchiu-2021-antiinflammatory-effects-of-fatty
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.